Virginia Kaklamani, MD, UT Southwestern Medical Center, Dallas, TX, talks on the predictive value of treatment response and residual disease after neoadjuvant therapy in ER-positive, HER2-positive, and triple-negative breast cancer (TNBC). In TNBC, the use of immunotherapy has allowed a higher number of patients to achieve a pathologic complete response (pCR). Results from the Phase III KATHERINE (NCT01772472) trial suggested that the use of trastuzumab emtansine is beneficial for patients with HER2-positive breast cancer who do not achieve a pCR. Currently, there is no post-treatment standard-of-care treatment options for patients who do not respond to endocrine therapy, however, new data is suggesting other targeted treatments could be given in the post-neoadjuvant setting to improve patients outcomes. This interview took place at the San Antonio Breast Cancer Symposium (SABCS) 2022 in San Antonio, TX.
These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.